Tebentafusp: a targeted hope against a resistant eye cancer

By Ana Espino | Published on August 07, 2025 | 3 min read 

#Tebentafusp #Melanoma #Immunotherapy  


Uveal melanoma is a rare intraocular tumor, accounting for 3–5% of all melanomas. It is characterized by a high hepatic metastatic tropism and a marked resistance to conventional systemic therapies. Despite effective local treatment options (radiotherapy, surgery), nearly 50% of patients develop metastases that are often refractory to chemotherapy and poorly responsive to standard immunotherapies such as immune checkpoint inhibitors.  

In the absence of effective systemic treatments, Tebentafusp represents a major therapeutic breakthrough. This bispecific agent can simultaneously bind the tumor-associated antigen gp100 and CD3 on T lymphocytes, thereby redirecting the immune response specifically toward tumor cells. Its efficacy appears particularly promising in HLA-A*02:01 positive patients, although several questions remain regarding the optimization of treatment protocols, a deeper understanding of response mechanisms, and possible combinations with other immunotherapies.  

This study was thus initiated to evaluate the efficacy and safety of Tebentafusp in patients with metastatic uveal melanoma, a population with a particularly poor prognosis.  

Tebentafusp: breakthrough or modest promise?  

 Four clinical studies involving 475 patients with metastatic uveal melanoma were included in the review. All patients had tumors expressing the gp100 antigen and carried the HLA-A*02:01 allele, which is essential for Tebentafusp’s efficacy.  

Participants received intravenous Tebentafusp at doses ranging from 20 µg to 68 µg. Treatments were administered weekly, with dose escalation in the early weeks to limit adverse effects. Outcomes assessed included overall survival, objective response rate, disease stabilization, tumor progression, and treatment tolerance.  

Results showed a one-year overall survival rate of 68%, with moderate heterogeneity across studies. The objective response rate remained low at 7%, with 37% of patients achieving stable disease and 52% experiencing tumor progression. No complete responses were reported. The most common adverse event was cytokine release syndrome (83%), followed by nausea (39%), fatigue (32%), and vomiting (25%). Although frequent, these events were mostly mild to moderate and manageable, rarely leading to treatment discontinuation. No significant increase in mortality or treatment-related severe complications was observed.    

A ray of hope in the shadow of uveal melanoma  

Metastatic uveal melanoma is a rare yet highly aggressive form of eye cancer, for which systemic treatment options remain very limited and ineffective once liver dissemination occurs. The main therapeutic challenge lies in the absence of actionable molecular targets and the poor efficacy of conventional immunotherapies. In response, Tebentafusp was developed as an innovative bispecific immunotherapy that simultaneously targets tumor cells and T lymphocytes.  

This study aimed to assess the clinical efficacy and safety of Tebentafusp in this high unmet medical need setting. The results suggest a significant short-term survival benefit, with moderate but encouraging clinical responses, particularly in HLA-A*02:01 positive patients. The safety profile appears to be overall manageable.  

However, the absence of complete responses, the heterogeneity of the available data, and the high frequency of adverse events call for cautious interpretation of the benefits. Large-scale phase 3 trials, with patient stratification based on predictive biomarkers and exploration of rational combinations, will be essential to confirm Tebentafusp’s role as a therapeutic pillar in metastatic uveal melanoma.   

Read next: Reprogrammer la graisse pour affamer la tumeur ?